414 related articles for article (PubMed ID: 2507171)
1. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
2. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
3. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
4. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
5. PGE2, but not TGF beta 2, in rabbit blastocoelic fluid regulates the cytotoxic activities of NK and LAK cells.
Bergeron D; Ouellette MJ; Lambert RD
J Reprod Immunol; 1997 Jul; 33(3):203-19. PubMed ID: 9255724
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
7. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
8. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells.
Xiao J; Brahmi Z
Cell Immunol; 1989 Sep; 122(2):295-306. PubMed ID: 2788512
[TBL] [Abstract][Full Text] [Related]
9. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
11. The relative resistance of lymphokine activated killer cells to suppression by prostaglandins and glucocorticoids.
Imir T; Sibbitt W; Bankhurst A
Prostaglandins Leukot Med; 1987 Jul; 28(2):111-8. PubMed ID: 3498171
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer (LAK) cells: III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells.
Leung KH
Cancer Immunol Immunother; 1991; 34(1):31-6. PubMed ID: 1760808
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant interferon-gamma and interleukin-2 on the generation of lymphokine-activated killer cells in vitro.
Findley HW; Nasr S; Afify Z; Hnath R; Waldrep K; Ragab AH
Cancer Invest; 1990; 8(5):493-500. PubMed ID: 2124946
[TBL] [Abstract][Full Text] [Related]
15. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
16. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
17. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.
Cesano A; Oberholtzer E; Contarini M; Geuna M; Bellone G; Matera L
Immunopharmacology; 1994; 28(1):67-75. PubMed ID: 7928303
[TBL] [Abstract][Full Text] [Related]
18. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction.
Singh KP; Gupta RK; Shau H; Ray PK
Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017
[TBL] [Abstract][Full Text] [Related]
19. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
20. Isolation of human NK cells and generation of LAK activity.
Whiteside TL
Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
